![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
DP Devine, P Leone, D Pocock and RA Wise
Department of Psychology, Concordia University, Montreal, Quebec, Canada.
In vivo microdialysis was used to assess the involvement of ventral tegmental area (VTA) mu, delta, and kappa opioid receptors in modulation of basal extracellular ventral striatal dopamine (DA) and DA- metabolite concentrations. Independent groups of chloral hydrate- anesthetized rats were given VTA microinjections of selective opioid agonists, and extracellular ventral striatal DA and DA-metabolite concentrations were assayed using HPLC. VTA microinjections of [D-Ala2, N-Me-Phe4-Gly5-ol]-enkephalin (DAMGO; a mu agonist) and [D-Pen2, D- Pen5]-enkephalin (DDDPE; a delta agonist) each caused dose-orderly increases in ventral striatal DA and DA-metabolite concentrations. The effective concentrations of DPDPE were 100- to 1000-fold higher than the effective concentrations of DAMGO. VTA microinjections of (trans- (dl)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclo-hexyl]- benzeneacetamide) methane sulfonate hydrate (U-50,488H); a kappa agonist) failed to alter ventral striatal DA concentrations at any dose tested, but subsequent systemic injections significantly decreased DA and DA-metabolite concentrations. Pretreatment with VTA microinjections of 17-cyclopropylmethyl-6,7-dehydro-4,5-epoxy-3,14-dihydroxy-6,7,2',3'- indolmorphinan hydrochloride (naltrindole; a delta antagonist) (delta antagonist) antagonized VTA DPDPE-mediated increases in ventral striatal DA and DA-metabolite concentrations but failed to antagonize VTA DAMGO-mediated increases. Pretreatment with D-Pen-Cys-Tyr-D-Trp-Orn- Thr-Pen-Thr-NH2 (CTOP; a mu antagonist) antagonized VTA DAMGO-mediated increases but failed to antagonize VTA DPDPE-mediated increases. Thus both mu and delta receptor agonist appear capable of increasing ventral striatal DA and DA-metabolite concentrations through selective actions on their preferred class of opioid receptors in the VTA. The increases in ventral striatal DA and DA-metabolite concentrations that are seen after systemic treatment with kappa opioid agonists appear not to involve VTA opioid receptors.
This article has been cited by other articles:
|
|
 |
|
  A. E. Sahr, D. K. Sindelar, J. T. Alexander-Chacko, B. J. Eastwood, C. H. Mitch, and M. A. Statnick Activation of mesolimbic dopamine neurons during novel and daily limited access to palatable food is blocked by the opioid antagonist LY255582 Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2008; 295(2): R463 - R471. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Britt and D. S. McGehee Presynaptic Opioid and Nicotinic Receptor Modulation of Dopamine Overflow in the Nucleus Accumbens J. Neurosci., February 13, 2008; 28(7): 1672 - 1681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Valdez, D. M. Platt, J. K. Rowlett, D. Ruedi-Bettschen, and R. D. Spealman {kappa} Agonist-Induced Reinstatement of Cocaine Seeking in Squirrel Monkeys: A Role for Opioid and Stress-Related Mechanisms J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 525 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Wager, D. J. Scott, and J.-K. Zubieta Placebo effects on human {micro}-opioid activity during pain PNAS, June 26, 2007; 104(26): 11056 - 11061. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. B. Rothman, D. L. Murphy, H. Xu, J. A. Godin, C. M. Dersch, J. S. Partilla, K. Tidgewell, M. Schmidt, and T. E. Prisinzano Salvinorin A: Allosteric Interactions at the {micro}-Opioid Receptor J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 801 - 810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. S. McGehee Nicotinic and Opioid Receptor Interactions in Nicotine Addiction Mol. Interv., December 1, 2006; 6(6): 311 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Carlezon Jr., C. Beguin, J. A. DiNieri, M. H. Baumann, M. R. Richards, M. S. Todtenkopf, R. B. Rothman, Z. Ma, D. Y.-W. Lee, and B. M. Cohen Depressive-Like Effects of the {kappa}-Opioid Receptor Agonist Salvinorin A on Behavior and Neurochemistry in Rats J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 440 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Mathews, X. Peng, W. Xiong, A. Zhang, S. S. Negus, J. L. Neumeyer, and J. M. Bidlack Characterization of a Novel Bivalent Morphinan Possessing {kappa} Agonist and {micro} Agonist/Antagonist Properties J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 821 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z.-X. Xi and E. A. Stein GABAergic MECHANISMS OF OPIATE REINFORCEMENT Alcohol Alcohol., September 1, 2002; 37(5): 485 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Bidlack, D. J. Cohen, J. P. McLaughlin, R. Lou, Y. Ye, and M. P. Wentland 8-Carboxamidocyclazocine: A Long-Acting, Novel Benzomorphan J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 374 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Schad, J. B. Justice Jr., and S. G. Holtzman Endogenous Opioids in Dopaminergic Cell Body Regions Modulate Amphetamine-Induced Increases in Extracellular Dopamine Levels in the Terminal Regions J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 932 - 938. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Mogil and G. W. Pasternak The Molecular and Behavioral Pharmacology of the Orphanin FQ/Nociceptin Peptide and Receptor Family Pharmacol. Rev., September 1, 2001; 53(3): 381 - 415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Pohorecky, A. Skiandos, X. Zhang, K. C. Rice, and D. Benjamin Effect of Chronic Social Stress on delta -Opioid Receptor Function in the Rat J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 196 - 206. [Abstract] [Full Text]
|
|
|
|
|
|
A. R. Burkey, E. Carstens, and L. Jasmin Dopamine Reuptake Inhibition in the Rostral Agranular Insular Cortex Produces Antinociception J. Neurosci., May 15, 1999; 19(10): 4169 - 4179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. K. Mello and S. S. Negus Effects of Kappa Opioid Agonists on Cocaine- and Food-Maintained Responding by Rhesus Monkeys J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 812 - 824. [Abstract] [Full Text]
|
|
|
|
|
|
Z.-X. Xi, S. A. Fuller, and E. A. Stein Dopamine Release in the Nucleus Accumbens during Heroin Self-Administration Is Modulated by Kappa Opioid Receptors: An In Vivo Fast-Cyclic Voltammetry Study J. Pharmacol. Exp. Ther., January 1, 1998; 284(1): 151 - 161. [Abstract] [Full Text]
|
|
|
|
|
|
B. Bontempi and F. R. Sharp Systemic Morphine-Induced Fos Protein in the Rat Striatum and Nucleus Accumbens Is Regulated by µ Opioid Receptors in the Substantia Nigra and Ventral Tegmental Area J. Neurosci., November 1, 1997; 17(21): 8596 - 8612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Negus, N. K. Mello, P. S. Portoghese, and C.-E. Lin Effects of Kappa Opioids on Cocaine Self-Administration by Rhesus Monkeys J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 44 - 55. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
